Want to see CPMD full AI Analyst Report?
Top Page
Cannapharmarx
(OTC:CPMD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.01
▲(400.00% Upside)
Action:Reiterated
Date:08/19/26
The score is primarily weighed down by weak financial performance—deeply negative margins, large ongoing losses, and negative equity—despite improving revenue and a near-term shift to modestly positive operating/free cash flow. Valuation offers limited support due to a negative P/E and no dividend yield data, while technicals could not be evaluated from the provided indicators.
Positive Factors
Revenue Growth
Rapid revenue growth indicates improving commercial traction and customer adoption. Although growth comes from a small base, continued expansion could strengthen the operating platform if the company converts sales into healthier gross margins.
Negative Factors
Persistent Negative Equity
A persistent equity deficit indicates accumulated losses have overwhelmed the capital structure. This weakens financial flexibility, limits access to conventional financing and increases the likelihood of dilution or restructuring over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Rapid revenue growth indicates improving commercial traction and customer adoption. Although growth comes from a small base, continued expansion could strengthen the operating platform if the company converts sales into healthier gross margins.
Read all positive factors
Cannapharmarx (CPMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.29M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue Growth46.45%
EPS Growth-1064.71%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding678,501,400
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-0.11
Price to Sales (P/S)2.53
P/FCF Ratio-4.34
Enterprise Value/Market Cap17.58
Enterprise Value/Revenue13.34
Enterprise Value/Gross Profit-16.54
Enterprise Value/Ebitda-2.88
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cannapharmarx Business Overview & Revenue Model
Company Description
CannaPharmaRX, Inc. is a Canadian enterprise actively involved in the cannabis sector. The company focuses on identifying, acquiring, and developing diverse projects for cultivating cannabis. Founded in 1998, its main offices are located in Calgar...
How the Company Makes Money
null...
Cannapharmarx Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.70M | 1.36M | 820.14K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.37M | -2.08M | -2.94M | -65.56K | -295.00K | -14.36K |
| EBITDA | -7.87M | -3.25M | -7.64M | -1.45M | -4.91M | -2.61M |
| Net Income | -11.32M | -11.13M | -9.91M | 3.69M | -8.53M | -8.83M |
Balance Sheet | ||||||
| Total Assets | 6.89M | 7.02M | 10.84M | 11.75M | 5.41M | 114.33K |
| Cash, Cash Equivalents and Short-Term Investments | 555.00 | 1.80K | 2.16K | 650.00 | 2.32K | 27.77K |
| Total Debt | 14.52M | 20.65M | 14.06M | 12.94M | 14.52M | 9.02M |
| Total Liabilities | 37.72M | 37.17M | 30.65M | 23.90M | 22.76M | 13.04M |
| Stockholders Equity | -30.83M | -30.15M | -19.81M | -12.15M | -17.34M | -12.93M |
Cash Flow | ||||||
| Free Cash Flow | 253.22K | -794.62K | -1.70M | -2.36M | -1.56M | -2.42M |
| Operating Cash Flow | 258.74K | -789.10K | -1.70M | -2.27M | -1.45M | -2.41M |
| Investing Cash Flow | -60.64K | -5.52K | 0.00 | -80.63K | -116.00K | 493.62K |
| Financing Cash Flow | 156.50K | 794.27K | 1.70M | 2.35M | 1.40M | 1.30M |
Cannapharmarx Risk Analysis
Cannapharmarx disclosed 63 risk factors in its most recent earnings report. Cannapharmarx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
While a major part of our business strategy is to pursue strategic acquisitions, we may not be able to identify businesses for which we can obtain necessary financing to acquire on acceptable terms, face risks due to additional indebtedness, and our acquisition strategy may incur significant costs or expose us to substantial risks inherent in the acquired business's operations. Q4, 2022
2.
We may not be able to protect intellectual property that we hope to acquire, which could adversely affect our business. Q4, 2022
Cannapharmarx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $4.84M | >-0.01 | -72.72% | ― | -34.06% | 79.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.29M | -0.12 | 34.30% | ― | 46.45% | -1064.71% | |
44 Neutral | $7.99M | -0.18 | 289.35% | ― | -7.58% | -30.33% | |
44 Neutral | $5.32M | -1.55 | -33.59% | ― | 10.01% | 95.01% | |
38 Underperform | $946.74K | -1,062.50 | -3.03% | ― | -11.91% | -285.23% |
* Healthcare Sector Average
CPMD
Cannapharmarx
―
―
―
XWEL
XWELL
0.95
-0.15
-13.64%
INM
InMed Pharmaceuticals
1.59
-0.63
-28.38%
YCBD
cbdMD
0.49
-0.17
-25.76%
LEXX
Lexaria Bioscience
11.51
-0.48
-4.00%
IMCC
IM Cannabis Corp
0.11
-2.16
-95.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.